U.S. markets closed
  • S&P 500

    4,158.24
    +100.40 (+2.47%)
     
  • Dow 30

    33,212.96
    +575.77 (+1.76%)
     
  • Nasdaq

    12,131.13
    +390.48 (+3.33%)
     
  • Russell 2000

    1,887.90
    +49.66 (+2.70%)
     
  • Crude Oil

    115.07
    +0.98 (+0.86%)
     
  • Gold

    1,857.30
    +3.40 (+0.18%)
     
  • Silver

    22.14
    +0.17 (+0.77%)
     
  • EUR/USD

    1.0739
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    2.7430
    -0.0130 (-0.47%)
     
  • GBP/USD

    1.2631
    +0.0025 (+0.20%)
     
  • USD/JPY

    127.0850
    -0.0170 (-0.01%)
     
  • BTC-USD

    29,001.23
    +172.32 (+0.60%)
     
  • CMC Crypto 200

    625.79
    -3.71 (-0.59%)
     
  • FTSE 100

    7,585.46
    +20.54 (+0.27%)
     
  • Nikkei 225

    26,781.68
    +176.84 (+0.66%)
     

Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In Noise

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Frequency Therapeutics Inc (NASDAQ: FREQ) shared the results from its FX-322-113 study of FX-322 in severe sensorineural hearing loss (SNHL).

  • The Phase 1b study, FX-322, was associated with a hearing signal, as shown by improvements by four subjects in a sentence-in-noise test.

  • In the FX-322-113 study, BKB-SIN test improvements were observed in four subjects, all of whom exceeded the 95% critical difference of 3.1 dB SNR, with two subjects showing a 6 dB response.

  • A single placebo patient had a 3.6 dB change.

  • In the study, subjects did not show substantial changes in speech perception measures in quiet. The safety profile in the study was favorable, and no treatment-related serious adverse events were reported.

  • BKB-SIN is a validated test designed for severe SNHL populations, measuring the change in signal-to-noise ratios required for a subject to correctly repeat words in a sentence.

  • Related Link: Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors.

  • Price Action: FREQ shares are up 3.00% at $5.68 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.